Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
DDDr. Dereck Mush, MD, MBA
Jun 5
Charm Therapeutics
Applies 3D deep learning to model protein-ligand interactions for small molecule design.
What they do
The company uses its proprietary deep learning platform, DragonFold, to predict the structures of proteins and identify how small molecules can bind to them. This technology helps researchers discover novel therapeutics for cancer and other hard to treat diseases.
The record
- Vertical
- Biotech & Pharma
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2021
- Total funding
- $50M raised
Notable investors: F-Prime Capital, OrbiMed, General Catalyst, Khosla Ventures.
Also in Biotech & Pharma
Related on The Signal
The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
DDDr. Dereck Mush, MD, MBA
Jul 16
AI is moving upstream, from molecule design into disease target identification itself
DDDr. Dereck Mush, MD, MBA
Mar 18
The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
DDDr. Dereck Mush, MD, MBA
May 15